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Background: Hormone receptor status is an important prognostic and therapeutic tool in breast cancer. The
objectives of our study were to create a database of breast cancer patients in Central Kerala between January 2010
and December 2012 and analyze the proportions of estrogen receptor and progesterone receptor positivity in
premenopausal and postmenopausal women with breast cancer.
Methods: Estrogen and progesterone receptor status were evaluated by immunohistochemistry. The chi-square test
was used for statistical analysis.
Results: The median age at diagnosis was 50 years while the mean age was 51.92 (SD = 11.78). 56.1% of
premenopausal and 47.4% of postmenopausal patients were found to be ER positive, while PR positivity was 47.7%
and 34.7% respectively in the premenopausal and postmenopausal age groups.
Conclusions: The proportions of ER and PRnegative tumors were found to be lower than reported in earlier studies
on Indian populations. Contrary to expectations, the proportions of ER and PRpositivity were found to be higher in the
premenopausal age group.
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Estrogen receptor (ER) status is an important predictive
and prognostic factor in breast cancer, and determination
of ER and progesterone receptor (PR) status of patients
with breast carcinoma is now standard practice [1].
Though the incidence of breast cancer has been on a
steady increase in Kerala [2], there have been very few
studies of breast cancer in the state. This study was
conducted in Government Medical College, Thrissur, a
tertiary-care hospital in central Kerala. The objectives of
our study were to create a database of patients in central
Kerala who were detected to have breast cancer between
January 2010 and December 2012 and to analyze the
proportions of ER and PR positivity in premenopausal
and postmenopausal women with breast carcinoma.* Correspondence: gautham1988@gmail.com; tbculas@gmail.com
Government Medical College, Thrissur, Kerala, India
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The study was conducted between 1 January 2010 and 31
December 2012 utilizing data available at the Department
of Pathology, Government Medical College, Thrissur. Fe-
male patients with histologically proven primary breast
cancer who were treated at the Department of Surgery,
Government Medical College, Thrissur were made part of
the study. Patients whose hormone receptor status was
not determined were excluded from the study. A total of
450 patients were studied.
All hormone receptor studies were done on post-
mastectomy specimens, or tissue samples obtained by
core-cut biopsy prior to anterior chemotherapy. In 2010
and 2011, ER status was determined using the BioGenex
monoclonal mouse IgG1 (Clone 1D5) and PR status using
BioGenex monoclonal mouse IgG1 (Clone 1A6). Antigen
retrieval was done using the BioGenex EZ Retriever sys-
tem. In 2012, DakoEnVision + System-HRP reagent was
used for identification of antigens in paraffin-embedded
tissues. Pressure cooking was used for antigen retrieval.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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used to study ER status. Monoclonal mouse IgG1 (Clone
PgR 636) was used to determine PR status.
The premenopausal group consisted of patients who
were 50 years or younger and the postmenopausal group
of patients aged 51 years and older. The Early Breast
Cancer Trialists’ Collaborative Group has used similar
criteria to define menopause when menopausal status was
not consistently defined across trials [3]. The median age
at natural menopause has also been established to be
51 years [4,5]. The chi-square test was used for obtaining
P-values and determining statistical significance. P-values
lower than 0.05 were considered statistically significant.
Results
Out of the 450 cases of breast cancer that were studied,
237 women were premenopausal and 213 were postmeno-
pausal. The ages of the study subjects ranged from 26 to
90 years. The median age was 50 years. In the premeno-
pausal age group ER was positive in 133 (56.1%) patients
and PR was positive in 113 (47.7%). The number of pre-
menopausal patients who were both ER and PRpositive
was 102 (43.0%). In the postmenopausal age group of 213
patients, 101 (47.4%) were ERpositive and 74 (34.7%) were
PRpositive: 72 patients (33.8%) were positive for both ER
and PR. Detailed analysis by age is shown in Table 1.
Discussion
It is now well-established that ERpositive tumors are
associated with better overall survival compared to
ERnegative tumors [6]. Determination of the hormone
receptor status has been routinely performed for breast
cancer patients in our institution from the year 2008. Al-
though the American Society of Clinical Oncology (ASCO)
2010 guidelines recommend that ER and PR assays be con-
sidered positive if at least 1% of tumor nuclei are positive
in the sample being tested [7], earlier studies have used a
10% cutoff. Because the definition of hormone receptor
positivity varies as mentioned, results obtained using the
two criteria have been summarized in Table 2.Table 1 Age-wise analysis of study subjects




21 to 30 09 04 (44.4%) 05 (55
31 to 40 73 43 (58.9%) 37 (50
41 to 50 155 86 (55.4%) 71 (45
51 to 60 117 51 (43.6%) 40 (34
61 to 70 69 32 (46.4%) 23 (33
71 to 80 22 15 (68.2%) 10 (45
81 to 90 05 03 (60.0%) 01 (20The peak prevalence of breast cancer in central Kerala
was found to be in the 41 to 50 years age group (Figure 1).
The median age at diagnosis was 50 years and the mean
age was 51.92 (SD 11.78). In comparison, the median age
at diagnosis for cancer of the breast in the US was 61 years
[8]. Because the majority of patients in India present with
a higher tumor-grade and a more advanced stage at diag-
nosis [9,10] when compared to those in the US [8], it is
likely that the actual age of onset of breast carcinoma in
the Indian patient is lower by well over a decade. This
younger age at onset of breast cancer can in part be
explained by racial differences [10].
Data from earlier studies conducted in India reveal a
higher proportion of ERnegative breast cancers when
compared to the US or Western Europe; the reasons for
this are several - technical failures, younger age of pa-
tients, and a higher grade or advanced stage at presenta-
tion [8-13]. In our study, the overall ERpositivity was
found to be 52.0%. The average ERpositivity for white
women in the US is 77% [8]. Studies done in India and
in Indian emigrants have found ERpositivity in Indian
women to be 34.5% [14], 35.88% [12], 37.83% [15], 38.6%
[11], 49.2% [13], 50.5% [9], and 55.1% [16]. ERpositivity
in premenopausal and postmenopausal women was found
to be 56.1% and 47.4% respectively. This difference was
not found to be statistically significant (P-value 0.065).
Only one earlier study done in India looks at the differ-
ences in ERstatus with respect to menopausal status;
ERpositivity therein was found to be 23.1% in premeno-
pausal women and 36.6% in postmenopausal women [14].
In our series 41.5% of patients were PRpositive while
55% of white women in the US are PRpositive [8]. Other
studies from India put PRpositivity at 33.3% [11], 36.4%
[14], and 42% [9]. The proportions of PRpositive tumors
in the premenopausal and postmenopausal age groups
were found to be 47.7% and 34.7% respectively (P-value
0.005). Kaul et al. in their study conducted in the Hima-
layan Region of Northern India found PRpositivity to be
23.1% and 39.0% respectively in premenopausal and
postmenopausal women [14].itive,
r (%)
Both ER and PRpositive,
number (%)
Both ER and PRnegative,
number (%)
.6%) 04 (44.4%) 04 (44.4%)
.7%) 35 (47.9%) 28 (38.4%)
.8%) 63 (40.6%) 61 (39.4%)
.2%) 39 (33.3%) 65 (55.6%)
.4%) 23 (33.3%) 37 (53.6%)
.5%) 09 (40.9%) 06 (27.3%)
.0%) 01 (20.0%) 02 (40.0%)




10% cutoff 1% cutoff (ASCO 2010)
Pre-menopausal Post-menopausal P-value Pre-menopausal Post-menopausal P-value
ERpositivity 56.1% 47.4% 0.065 60.8% 54.5% 0.177
PRpositivity 47.4% 34.7% 0.005 58.7% 47.8% 0.022
ER, estrogen receptor; PR, progesterone, PR.
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hormone receptor positivity. Studies in the US show that
Asians have a lower ER positivity rate than non-Hispanic
whites [17,18]. Our findings concur with these studies.
There also appears to be geographical variations in ER
positivity within India. The diet and lifestyle of our study
population in Kerala, a state in the Southern tip of India
with an expansive coastline, differs considerably from those
of people in the North of the country. Seafood forms a
prominent portion of the Kerala diet. Kerala stands first in
the Human Development Index (HDI) among states in
India, with an HDI of 0.790 (2011) against a national aver-
age of 0.467 (2011). Kerala also tops the country in every
healthcare parameter, and awareness about breast cancer is
also high among the people. These factors could explain
the higher proportion of ER and PRpositive breast cancer
in Kerala.
The immunohistochemistry technique used by our
laboratory is standardized and is comparable with
those used by other institutions in India and inter-
nationally [12-14,16]. Poor tissue handling or process-
ing is unlikely to have altered the results obtained, as
our institution has strict protocols and quality control
measures.Figure 1 Age distribution of study subjects. The peak prevalence of breaConclusions
Contrary to what has been reported in earlier studies,
we found the proportions of ER and PRpositivity to be
higher in the premenopausal age group. Though India
has a higher proportion of ERnegative breast cancer
than the West, the situation is not as dismal as has
been previously thought. Also, women in our series
tend to be younger than their Western counterparts.
Better tissue handling and processing will help decrease
the number of false-negatives, and will ensure that hormo-
nal manipulation is made available to a greater number of
patients with breast cancer, thus improving the outcome
of the disease.
The causes leading to the loss of the ER mechanism
are currently being investigated, and if proven to be an
epigenetic phenomenon, as has been postulated [19], it
might in the near future be possible to convert ERnegative
tumors to an ERpositive phenotype, thus bringing to an
end the era of non-specific chemotherapy. Moreover, in
a resource-limited setting like ours, a subset of premen-
opausal women who are ERpositive and have completed
their families, but refuse adjuvant chemotherapy ther-
apy can be offered the alternative option of surgical
oophorectomy.st cancer in central Kerala was found to be in the 41 to 50 years age group.
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